Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001558370-21-005442
Filing Date
2021-04-30
Accepted
2021-04-30 17:15:03
Documents
79
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A ettx-20201231x10ka.htm   iXBRL 10-K/A 1095450
2 EX-31.1 ettx-20201231xex31d1.htm EX-31.1 9458
3 EX-31.2 ettx-20201231xex31d2.htm EX-31.2 10890
4 EX-32.1 ettx-20201231xex32d1.htm EX-32.1 5289
  Complete submission text file 0001558370-21-005442.txt   6646531

Data Files

Seq Description Document Type Size
5 EX-101.SCH ettx-20201231.xsd EX-101.SCH 58686
6 EX-101.CAL ettx-20201231_cal.xml EX-101.CAL 60200
7 EX-101.DEF ettx-20201231_def.xml EX-101.DEF 193719
8 EX-101.LAB ettx-20201231_lab.xml EX-101.LAB 528115
9 EX-101.PRE ettx-20201231_pre.xml EX-101.PRE 392250
10 EXTRACTED XBRL INSTANCE DOCUMENT ettx-20201231x10ka_htm.xml XML 1202528
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

EIN.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38670 | Film No.: 21879682
SIC: 2834 Pharmaceutical Preparations